Two Sigma Advisers
TGTX icon

Two Sigma Advisers’s TG Therapeutics TGTX Stock Holding History

Two Sigma Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-599,600
Closed -$17.9M – 1934
2025
Q4 		$17.9M Buy
599,600
+171,400
+40% +$5.6M 0.03% 381
2025
Q3 		$15.5M Buy
428,200
+304,700
+247% +$10M 0.03% 385
2025
Q2 		$4.44M Sell
123,500
-8,900
-7% -$331K 0.01% 782
2025
Q1 		$5.22M Buy
132,400
+121,700
+1,137% +$4.09M 0.01% 773
2024
Q4 		$322K Sell
10,700
-214,800
-95% -$6.16M ﹤0.01% 1953
2024
Q3 		$5.27M Buy
225,500
+59,400
+36% +$1.3M 0.01% 690
2024
Q2 		$2.95M Buy
+166,100
New +$2.65M 0.01% 991
2023
Q4 		– Sell
-951,200
Closed -$7.95M – 2642
2023
Q3 		$7.95M Buy
951,200
+218,600
+30% +$3.05M 0.02% 554
2023
Q2 		$18.2M Buy
732,600
+209,000
+40% +$5.4M 0.05% 324
2023
Q1 		$7.87M Buy
523,600
+176,300
+51% +$2.68M 0.02% 631
2022
Q4 		$4.11M Buy
347,300
+142,600
+70% +$1.03M 0.01% 861
2022
Q3 		$1.21M Buy
204,700
+55,300
+37% +$363K ﹤0.01% 1427
2022
Q2 		$635K Buy
149,400
+69,100
+86% +$431K ﹤0.01% 1821
2022
Q1 		$764K Buy
+80,300
New +$929K ﹤0.01% 1781
2021
Q1 		– Sell
-7,300
Closed -$380K – 2722
2020
Q4 		$380K Buy
+7,300
New +$247K ﹤0.01% 1967
2019
Q2 		– Sell
-45,200
Closed -$363K – 2433
2019
Q1 		$363K Sell
45,200
-10,600
-19% -$57.3K ﹤0.01% 1923
2018
Q4 		$229K Buy
55,800
+12,800
+30% +$63.6K ﹤0.01% 2087
2018
Q3 		$241K Sell
43,000
-9,100
-17% -$104K ﹤0.01% 2031
2018
Q2 		$685K Buy
52,100
+21,400
+70% +$294K ﹤0.01% 1785
2018
Q1 		$436K Buy
+30,700
New +$392K ﹤0.01% 1866
2017
Q4 		– Sell
-10,200
Closed -$121K – 2371
2017
Q3 		$121K Sell
10,200
-2,100
-17% -$23.9K ﹤0.01% 2107
2017
Q2 		$124K Buy
+12,300
New +$138K ﹤0.01% 2167

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Advisers's TGTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 599,600 shares — an estimated $17.9M sold.

Two Sigma Advisers first reported a position in TGTX in Q2 2017 and held it in 22 quarters. The position peaked at $18.2M in Q2 2023. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 599,600 TG Therapeutics shares in Q1 2026, an estimated $17.9M.
  • Two Sigma Advisers first reported a position in TG Therapeutics in Q2 2017 and held it in 22 quarters.
  • Two Sigma Advisers's TG Therapeutics position peaked at $18.2M in Q2 2023.
  • 364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.